Rezolute is trading 5.3% down at $5.03 today with no fresh company-specific catalysts, likely reflecting positioning after a strong move earlier in the week.
- The decline follows a prior FDA-meeting update that lifted shares, but no new FDA decisions, earnings releases, or analyst actions have been reported for the July 24 session.
- Broader biotech sentiment remains mixed and trading in the sector continues to be choppy, contributing to the stock's recent volatility.